Postmarketing Surveillance Study With MOBEC®

Boehringer Ingelheim

Status: Completed

Conditions: Osteoarthritis

Treatments: Drug: MOBEC

Study type: Observational

Funder types: Industry

Identifiers

NCT02182726

107.245

Details and patient eligibility

About

The aim of the study is to investigate

• the indication for MOBEC in a dose of 15 mg per day
• the treatments patients were receiving before switching to 15 mg MOBEC
• how treatment with 15 mg is assessed compared with previous treatment
• how effective and safe treatment with 15 mg MOBEC is considered

Enrollment: 4,760 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• An indication for a treatment with 15 mg MOBEC of at least four weeks

  • the symptomatic short-term treatment of osteoarthritis
  • the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg)
  • the symptomatic treatment of ankylosing spondylitis

Exclusion criteria

• Treatment with MOBEC prior to the start of the study
• Patients with any of the general or specific contraindications of MOBEC

Trial design

4,760 participants in 1 patient group

MOBEC

Treatment:

Drug: MOBEC